Zhen Huang
Director/Board Member bei WALVAX BIOTECHNOLOGY CO., LTD.
Vermögen: 66 Mio $ am 31.03.2024
Profil
Zhen Huang currently works at Walvax Biotechnology Co., Ltd., as Vice Chairman from 2019, Shanghai Zerun Biotechnology Co., Ltd., as Director, and Yuxi Walvax Biotechnology Co., Ltd., as President.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.06.2023 | 17 698 729 ( 1,14% ) | 38 Mio $ | 31.03.2024 | |
| 30.09.2023 | 13 274 047 ( 28,09% ) | 28 Mio $ | 31.03.2024 |
Aktive Positionen von Zhen Huang
| Unternehmen | Position | Beginn |
|---|---|---|
| WALVAX BIOTECHNOLOGY CO., LTD. | Director/Board Member | 22.08.2019 |
| Yuxi Walvax Biotechnology Co., Ltd. | President | - |
Shanghai Zerun Biotechnology Co., Ltd.
 Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China. | Director/Board Member | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| WALVAX BIOTECHNOLOGY CO., LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Yuxi Walvax Biotechnology Co., Ltd. | |
Shanghai Zerun Biotechnology Co., Ltd.
Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China. | Health Technology |
